Close

ABCC8

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The protein encoded by this gene is a member of the superfamily of ATP-binding cassette transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies. This protein is a member of the MRP subfamily which is involved in multi-drug resistance. This protein functions as a modulator of ATP-sensitive potassium channels and insulin release. Mutations and deficiencies in this protein have been observed in patients with hyperinsulinemic hypoglycemia of infancy, an autosomal recessive disorder of unregulated and high insulin secretion. Mutations have also been associated with non-insulin-dependent diabetes mellitus type II, an autosomal dominant disease of defective insulin secretion. Alternatively spliced transcript variants have been found for this gene.
  • CAR Vector Products

  • DMAb

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-CQ0001 Anti-ABCC8 (S289-16) h(41BB-CD3ζ) CAR, pCDCAR1 Human, Mouse, Rat, Hamster S289-16 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ0002 Anti-ABCC8 (CBXS-4921) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBXS-4921 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ3425 Anti-ABCC8 (S289-16) h(CD28-CD3ζ) CAR, pCDCAR1 Human, Mouse, Rat, Hamster S289-16 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ3426 Anti-ABCC8 (CBXS-4921) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBXS-4921 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY1732 Anti-ABCC8 (CBFYM-0255) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBFYM-0255 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY1733 Anti-ABCC8 (CBFYM-0310) h(41BB-CD3ζ) CAR, pCDCAR1 Mouse, Human CBFYM-0310 Rabbit scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY1734 Anti-ABCC8 (CBFYM-0833) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBFYM-0833 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY1735 Anti-ABCC8 (CBFYM-0834) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBFYM-0834 Rat scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY4985 Anti-ABCC8 (CBFYM-0255) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBFYM-0255 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY4986 Anti-ABCC8 (CBFYM-0310) h(CD28-CD3ζ) CAR, pCDCAR1 Mouse, Human CBFYM-0310 Rabbit scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY4987 Anti-ABCC8 (CBFYM-0833) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBFYM-0833 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY4988 Anti-ABCC8 (CBFYM-0834) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBFYM-0834 Rat scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.